From: April Cashin-Garbutt
Sent: Thursday, May 05, 2016 11:09 AM
To: [log in to unmask]
Subject: Parkinson's Disease - May 4, 2016 Edition
Researchers explore changes in Parkinson's-affected cells at different stages of the disease
Can't see this email? View it online
May 4, 2016
Parkinson's Disease
The latest Parkinson's disease news from News Medical
Researchers explore changes in Parkinson's-affected cells at different stages of the disease It's an unsettling thought: You could be walking around for 20 years developing Parkinson's disease and not even know it.
Dopamine neuron transplants controlled by designer drug may fight Parkinson's disease in mice A University of Wisconsin-Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell. The cells in question are neurons and make the neurotransmitter dopamine, whose deficiency is the culprit in the widespread movement disorder Parkinson's disease.
Oral administration of Jakinibs reduces Parkinson's disease pathogenesis in rat model University of Alabama at Birmingham researchers report the first documentation that suppressing a key cell-signaling pathway in a rat model of Parkinson's disease reduces pathogenesis. Oral administration of AZD1480 — one of the JAK/STAT pathway inhibitors generally known as Jakinibs — lessened the destructive inflammation and nerve cell degradation in the area of the brain affected by Parkinson's.
Lund study shows transplanted nerve cells can survive for many years in diseased human brain In the late 1980s and over the 1990s, researchers at Lund University in Sweden pioneered the transplantation of new nerve cells into the brains of patients with Parkinson's disease. The outcomes proved for the first time that transplanted nerve cells can survive and function in the diseased human brain. Some patients showed marked improvement after the transplantation while others showed moderate or no relief of symptoms.
Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease.
Snapshots of NMDA receptor activation may help in novel drug design Structural biologists at Cold Spring Harbor Laboratory and Janelia Research Campus/HHMI, have obtained snapshots of the activation of an important type of brain-cell receptor. Dysfunction of the receptor has been implicated in a range of neurological illnesses, including Alzheimer's disease, Parkinson's disease, depression, seizure, schizophrenia, autism, and injuries related to stroke.
Website: www.news-medical.net
Email: [log in to unmask]
Telephone: +44 (0)1625 615111
AZoNetwork UK Ltd.
Fence House, Fence Ave
Macclesfield, Cheshire
SK10 1LT, UK
Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.
Not interested anymore?
Update your Newsletter Subscriptions
Copyright © 2000-2016
Privacy Terms and Conditions
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
